GNRH1 and prostate carcinoma: ADT is usually given in the neoadjuvant, concurrent and adjuvant setting in HR prostate cancer, and consists of a luteinizing hormone-releasing hormone (LHRH) agonist, an LHRH agonist with a first-generation antiandrogen, or an LHRH antagonist.